Loading...

CymaBay Therapeutics

Nasdaq:CBAY
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CBAY
Nasdaq
$471M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • CymaBay Therapeutics has significant price volatility in the past 3 months.
CBAY Share Price and Events
7 Day Returns
-2.3%
NasdaqGS:CBAY
1.8%
US Pharmaceuticals
1.4%
US Market
1 Year Returns
-47.6%
NasdaqGS:CBAY
10.3%
US Pharmaceuticals
4.9%
US Market
CBAY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CymaBay Therapeutics (CBAY) -2.3% -46.8% -47.6% -47.6% 296.5% 5.5%
US Pharmaceuticals 1.8% 2.2% -1% 10.3% 13% 16.4%
US Market 1.4% 3.8% 3.5% 4.9% 44.8% 40.1%
1 Year Return vs Industry and Market
  • CBAY underperformed the Pharmaceuticals industry which returned 10.3% over the past year.
  • CBAY underperformed the Market in United States of America which returned 4.9% over the past year.
Price Volatility
CBAY
Industry
5yr Volatility vs Market

Value

 Is CymaBay Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CymaBay Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $6.86.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CymaBay Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CymaBay Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:CBAY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.31
NasdaqGS:CBAY Share Price ** NasdaqGS (2019-06-25) in USD $6.86
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.19x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.73x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CymaBay Therapeutics.

NasdaqGS:CBAY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CBAY Share Price ÷ EPS (both in USD)

= 6.86 ÷ -1.31

-5.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CymaBay Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • CymaBay Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does CymaBay Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:CBAY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
37.1%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.63x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CymaBay Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CymaBay Therapeutics's assets?
Raw Data
NasdaqGS:CBAY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.75
NasdaqGS:CBAY Share Price * NasdaqGS (2019-06-25) in USD $6.86
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.24x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.79x
NasdaqGS:CBAY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CBAY Share Price ÷ Book Value per Share (both in USD)

= 6.86 ÷ 3.75

1.83x

* Primary Listing of CymaBay Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CymaBay Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess CymaBay Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. CymaBay Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CymaBay Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CymaBay Therapeutics expected to grow at an attractive rate?
  • CymaBay Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • CymaBay Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • CymaBay Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:CBAY Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:CBAY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 37.1%
NasdaqGS:CBAY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 77.5%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:CBAY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:CBAY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 211 -141 44 8
2022-12-31 109 -111 -56 9
2021-12-31 17 -142 -121 9
2020-12-31 6 -114 -109 9
2019-12-31 0 -89 -97 9
NasdaqGS:CBAY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -71 -79
2018-12-31 -55 -73
2018-09-30 5 -41 -58
2018-06-30 5 -31 -48
2018-03-31 5 -24 -39
2017-12-31 10 -20 -28
2017-09-30 5 -19 -29
2017-06-30 5 -19 -27
2017-03-31 5 -19 -25
2016-12-31 -23 -27
2016-09-30 -23 -26
2016-06-30 -24 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CymaBay Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • CymaBay Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:CBAY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from CymaBay Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CBAY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.72 6.76 -2.44 9.00
2022-12-31 -0.65 2.46 -2.60 9.00
2021-12-31 -1.59 -0.58 -2.67 9.00
2020-12-31 -1.56 -0.91 -2.03 9.00
2019-12-31 -1.49 -1.36 -1.74 9.00
NasdaqGS:CBAY Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.31
2018-12-31 -1.25
2018-09-30 -1.08
2018-06-30 -0.97
2018-03-31 -0.94
2017-12-31 -0.79
2017-09-30 -0.99
2017-06-30 -1.06
2017-03-31 -1.04
2016-12-31 -1.14
2016-09-30 -1.10
2016-06-30 -1.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CymaBay Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CymaBay Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CymaBay Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CymaBay Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CymaBay Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CymaBay Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CymaBay Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CymaBay Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
CymaBay Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CymaBay Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CBAY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -78.62 16.67 15.98
2018-12-31 -72.55 14.38 14.38
2018-09-30 5.21 -58.14 10.52 12.44
2018-06-30 5.21 -47.81 9.45 10.46
2018-03-31 5.21 -39.21 12.06 8.35
2017-12-31 10.00 -27.56 12.39 6.93
2017-09-30 4.79 -29.47 12.33 6.23
2017-06-30 4.79 -27.11 12.25 6.11
2017-03-31 4.79 -25.17 10.89 6.20
2016-12-31 -26.67 9.65 6.19
2016-09-30 -25.70 8.60 5.81
2016-06-30 -25.68 8.67 5.60
2016-03-31 -20.05 8.74 5.62
2015-12-31 -15.53 8.87 5.33
2015-09-30 -22.27 9.41 5.71
2015-06-30 -22.37 8.89 7.08
2015-03-31 -24.18 8.27 4.44
2014-12-31 -31.92 8.19 4.20
2014-09-30 208.32 7.94 3.61
2014-06-30 257.15 6.94 1.50
2014-03-31 239.67 6.45 3.37
2013-12-31 243.99 4.87 3.36
2013-09-30 0.01 10.51 3.65 3.67
2013-06-30 2.93 -36.09 3.89 4.42
2013-03-31 2.94 -22.58 3.98 4.98
2012-12-31 3.05 -23.90 4.21 5.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CymaBay Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CymaBay Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CymaBay Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CymaBay Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CymaBay Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CymaBay Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CymaBay Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CymaBay Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CymaBay Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CymaBay Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • CymaBay Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CymaBay Therapeutics Company Filings, last reported 2 months ago.

NasdaqGS:CBAY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 257.63 0.00 264.76
2018-12-31 170.42 0.00 178.66
2018-09-30 188.13 0.00 198.15
2018-06-30 199.21 0.00 212.08
2018-03-31 212.20 5.36 229.54
2017-12-31 84.95 6.10 97.21
2017-09-30 86.50 6.81 102.17
2017-06-30 2.14 7.50 16.73
2017-03-31 9.23 8.16 23.40
2016-12-31 3.94 8.80 16.99
2016-09-30 10.21 9.42 23.13
2016-06-30 15.42 9.54 29.12
2016-03-31 21.85 9.42 35.25
2015-12-31 28.12 9.31 41.48
2015-09-30 33.49 9.20 46.85
2015-06-30 17.68 3.88 27.03
2015-03-31 18.27 4.19 32.79
2014-12-31 13.85 4.51 34.80
2014-09-30 26.13 4.67 42.63
2014-06-30 8.48 4.59 23.63
2014-03-31 11.38 4.51 28.53
2013-12-31 18.60 4.45 31.24
2013-09-30 20.11 4.37 32.08
2013-06-30 -14.69 13.75 3.56
2013-03-31 -12.48 13.75 5.62
2012-12-31 -9.87 13.74 7.73
  • CymaBay Therapeutics has no debt.
  • CymaBay Therapeutics has no debt compared to 5 years ago when it was 39.8%.
  • CymaBay Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • CymaBay Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess CymaBay Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CymaBay Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CymaBay Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CymaBay Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of CymaBay Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CymaBay Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CymaBay Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:CBAY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:CBAY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CymaBay Therapeutics has not reported any payouts.
  • Unable to verify if CymaBay Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CymaBay Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CymaBay Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of CymaBay Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess CymaBay Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CymaBay Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CymaBay Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CymaBay Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sujal Shah
COMPENSATION $1,938,017
AGE 45
TENURE AS CEO 2.3 years
CEO Bio

Mr. Sujal A. Shah has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah served as an Interim Chief Executive Officer and Interim President of Cymabay Therapeutics, Inc, from March 2017 to November 6, 2017 and as its Chief Financial Officer from December 6, 2013 to April 27, 2017 and as its Principal Financial & Accounting Officer until April 27, 2017. Mr. Shah served as an Acting Chief Financial Officer of Cymabay Therapeutics from June 27, 2012 to December 6, 2013. From 2010 to 2012, he served as a Director of Health Care Investment Banking Group for Citigroup. From 2004 to 2010, Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. He has been a Director of Cymabay Therapeutics, Inc., since April 25, 2017. Mr. Shah holds an MBA from Carnegie Mellon University - Tepper School of Business in 2004, an MS from Northwestern University in Biomedical Engineering in 1997 and a BS in Biomedical Engineering.

CEO Compensation
  • Sujal's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Sujal's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the CymaBay Therapeutics management team in years:

2.3
Average Tenure
56
Average Age
  • The tenure for the CymaBay Therapeutics management team is about average.
Management Team

Rob Wills

TITLE
Chairman
COMPENSATION
$184K
AGE
64

Sujal Shah

TITLE
President
COMPENSATION
$2M
AGE
45
TENURE
2.3 yrs

Dan Menold

TITLE
Vice President of Finance
COMPENSATION
$857K
AGE
48
TENURE
2.2 yrs

Charles McWherter

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$2M
AGE
63
TENURE
6.4 yrs

Paul Quinlan

TITLE
General Counsel & Corporate Secretary
COMPENSATION
$3M
AGE
55
TENURE
1.5 yrs

Pol Boudes

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
61
TENURE
5.2 yrs

Klara Dickinson-Eason

TITLE
Chief Regulatory & Compliance Officer
AGE
50
TENURE
0.4 yrs

Ken Boehm

TITLE
Vice President of Human Resources
TENURE
0.2 yrs

Patrick O'Mara

TITLE
Senior Vice President of Business Development
AGE
57
TENURE
2.4 yrs

Rob Martin

TITLE
Senior Vice President of Manufacturing & Nonclinical Development
AGE
56
TENURE
4.2 yrs
Board of Directors Tenure

Average tenure and age of the CymaBay Therapeutics board of directors in years:

3.7
Average Tenure
51
Average Age
  • The tenure for the CymaBay Therapeutics board of directors is about average.
Board of Directors

Sujal Shah

TITLE
President
COMPENSATION
$2M
AGE
45
TENURE
2.2 yrs

Carl Goldfischer

TITLE
Independent Director
COMPENSATION
$181K
AGE
59
TENURE
15.8 yrs

Rob Wills

TITLE
Chairman
COMPENSATION
$184K
AGE
64
TENURE
3.7 yrs

Kurt von Emster

TITLE
Independent Director
COMPENSATION
$175K
AGE
51
TENURE
10.2 yrs

Paul Truex

TITLE
Independent Director
COMPENSATION
$172K
AGE
49
TENURE
3.2 yrs

Jerrold Olefsky

TITLE
Member of Clinical Advisory Board and Member of Scientific Advisory Board

Steve Shoelson

TITLE
Member of Scientific Advisory Board

Morris Birnbaum

TITLE
Member of Scientific Advisory Board

Mayer Davidson

TITLE
Member of Clinical Advisory Board

Robert Gelfand

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
21. Dec 18 Buy Sujal Shah Individual 21. Dec 18 21. Dec 18 10,000 $6.54 $65,399
19. Dec 18 Sell Abingworth LLP Company 17. Dec 18 18. Dec 18 -142,381 $8.17 $-1,123,588
16. Oct 18 Buy Sujal Shah Individual 15. Oct 18 15. Oct 18 5,000 $9.90 $49,500
30. Jul 18 Buy Sujal Shah Individual 27. Jul 18 27. Jul 18 5,000 $10.90 $54,500
X
Management checks
We assess CymaBay Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CymaBay Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Read This Before Selling CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares

So we'll take a look at whether insiders have been buying or selling shares in CymaBay Therapeutics, Inc. … See our latest analysis for CymaBay Therapeutics The Last 12 Months Of Insider Transactions At CymaBay Therapeutics In the last twelve months, the biggest single purchase by an insider was when President Sujal Shah bought US$65k worth of shares at a price of US$6.54 per share. … NasdaqGS:CBAY Recent Insider Trading, May 24th 2019 CymaBay Therapeutics is not the only stock that insiders are buying.

Simply Wall St -

CymaBay Therapeutics (NASDAQ:CBAY) Shareholders Have Enjoyed A Whopping 445% Share Price Gain

Because CymaBay Therapeutics is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Simply Wall St -

Does CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Have A Volatile Share Price?

(NASDAQ:CBAY), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Why Fundamental Investors Might Love CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … Looking at the company as a whole, as a potential stock investment, I believe CBAY has a lot to offer.

Simply Wall St -

Read This Before Selling CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares

The Last 12 Months Of Insider Transactions At CymaBay Therapeutics. … President Sujal Shah made the biggest insider purchase in the last 12 months … Even though the purchase was made at a significantly lower price, we still think insider buying is a positive

Simply Wall St -

What does CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) Balance Sheet Tell Us About Its Future?

(NASDAQ:CBAY), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is CBAY right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

CymaBay Therapeutics Inc (NASDAQ:CBAY): What Does Its Beta Value Mean For Your Portfolio?

If you're interested in CymaBay Therapeutics Inc (NASDAQ:CBAY), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Breakeven On The Horizon For CymaBay Therapeutics Inc (NASDAQ:CBAY)

CymaBay Therapeutics Inc's (NASDAQ:CBAY):. … CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. … The US$807.48m market-cap posted a loss in its most recent financial year of -US$27.56m and a latest trailing-twelve-month loss of -US$39.21m leading to an even wider gap between loss and breakeven.

Simply Wall St -

Company Info

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Details
Name: CymaBay Therapeutics, Inc.
CBAY
Exchange: NasdaqGS
Founded: 1988
$471,254,854
68,696,043
Website: http://www.cymabay.com
Address: CymaBay Therapeutics, Inc.
7575 Gateway Boulevard,
Suite 110,
Newark,
California, 94560,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CBAY Common Stock Nasdaq Global Select US USD 24. Jan 2014
DB C0I Common Stock Deutsche Boerse AG DE EUR 24. Jan 2014
LSE 0I5P Common Stock London Stock Exchange GB USD 24. Jan 2014
Number of employees
Current staff
Staff numbers
43
CymaBay Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 01:11
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/06/24
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.